Clients

Panbela Therapeutics, Inc.

Company Snapshot: Panbela Therapeutics, Inc.

PBLA
Last Change Volume High Low

Company Overview

Panbela Therapeutics Inc is a clinical stage drug development company. It is engaged in the commercial development of a proprietary polyamine analogue for pancreatic cancer and for the second indication in chronic pancreatitis. The firm has developed a polyamine analogue compound referred as SBP-101 for the exocrine pancreas, with therapeutic potential for both pancreatic cancer and pancreatitis indications.

Client News

  1. Feb 15 2024 Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
  2. Feb 1 2024 Panbela Announces Closing of Approximately $9.0 Million Public Offering
  3. Jan 30 2024 Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
  4. Jan 29 2024 Panbela Announces Pricing of Approximately $9.0 Million Public Offering